Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 16354721)

1.

Transgenic plant production of Cyanovirin-N, an HIV microbicide.

Sexton A, Drake PM, Mahmood N, Harman SJ, Shattock RJ, Ma JK.

FASEB J. 2006 Feb;20(2):356-8. Epub 2005 Dec 14.

2.

Design, expression, and characterization of a multivalent, combination HIV microbicide.

Sexton A, Harman S, Shattock RJ, Ma JK.

FASEB J. 2009 Oct;23(10):3590-600. doi: 10.1096/fj.09-131995. Epub 2009 May 26.

3.

Development of rhizosecretion as a production system for recombinant proteins from hydroponic cultivated tobacco.

Drake PM, Barbi T, Sexton A, McGowan E, Stadlmann J, Navarre C, Paul MJ, Ma JK.

FASEB J. 2009 Oct;23(10):3581-9. doi: 10.1096/fj.09-131771. Epub 2009 May 26.

4.

The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1.

Giomarelli B, Provvedi R, Meacci F, Maggi T, Medaglini D, Pozzi G, Mori T, McMahon JB, Gardella R, Boyd MR.

AIDS. 2002 Jul 5;16(10):1351-6.

PMID:
12131211
5.

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.

Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH 2nd, Buckheit RW Jr, Nara PL, Pannell LK, Sowder RC 2nd, Henderson LE.

Antimicrob Agents Chemother. 1997 Jul;41(7):1521-30.

6.

Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development.

Colleluori DM, Tien D, Kang F, Pagliei T, Kuss R, McCormick T, Watson K, McFadden K, Chaiken I, Buckheit RW Jr, Romano JW.

Protein Expr Purif. 2005 Feb;39(2):229-36.

PMID:
15642474
7.

Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium.

Mori T, Gustafson KR, Pannell LK, Shoemaker RH, Wu L, McMahon JB, Boyd MR.

Protein Expr Purif. 1998 Mar;12(2):151-8.

PMID:
9518455
8.

Optimization of the expression of the HIV fusion inhibitor cyanovirin-N from the tobacco plastid genome.

Elghabi Z, Karcher D, Zhou F, Ruf S, Bock R.

Plant Biotechnol J. 2011 Jun;9(5):599-608. doi: 10.1111/j.1467-7652.2011.00598.x. Epub 2011 Feb 11.

PMID:
21309998
9.

Transformation of Althaea officinalis L. by Agrobacterium rhizogenes for the production of transgenic roots expressing the anti-HIV microbicide cyanovirin-N.

Drake PM, de Moraes Madeira L, Szeto TH, Ma JK.

Transgenic Res. 2013 Dec;22(6):1225-9. doi: 10.1007/s11248-013-9730-7. Epub 2013 Jul 13.

PMID:
23852261
10.

Optimisation of contained Nicotiana tabacum cultivation for the production of recombinant protein pharmaceuticals.

Colgan R, Atkinson CJ, Paul M, Hassan S, Drake PM, Sexton AL, Santa-Cruz S, James D, Hamp K, Gutteridge C, Ma JK.

Transgenic Res. 2010 Apr;19(2):241-56. doi: 10.1007/s11248-009-9303-y. Epub 2009 Jul 9.

PMID:
19588264
11.

A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity.

Fromme R, Katiliene Z, Giomarelli B, Bogani F, Mc Mahon J, Mori T, Fromme P, Ghirlanda G.

Biochemistry. 2007 Aug 14;46(32):9199-207. Epub 2007 Jul 18.

PMID:
17636873
12.

Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.

Mori T, Shoemaker RH, Gulakowski RJ, Krepps BL, McMahon JB, Gustafson KR, Pannell LK, Boyd MR.

Biochem Biophys Res Commun. 1997 Sep 8;238(1):218-22.

PMID:
9299482
13.

Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts.

Mori T, Barrientos LG, Han Z, Gronenborn AM, Turpin JA, Boyd MR.

Protein Expr Purif. 2002 Oct;26(1):42-9.

PMID:
12356469
14.

[Expression, purification and activity determination of cyanovirin-N].

Chen W, Han B, Qian C, Liu Q, Xiong S.

Sheng Wu Gong Cheng Xue Bao. 2010 Apr;26(4):538-44. Chinese.

PMID:
20575444
15.

Development of a cyanovirin-N-HIV-1 gp120 binding assay for high throughput screening of natural product extracts by time-resolved fluorescence.

McMahon JB, Beutler JA, O'Keefe BR, Goodrum CB, Myers MA, Boyd MR.

J Biomol Screen. 2000 Jun;5(3):169-76.

PMID:
10894760
16.

Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).

Gandhi MJ, Boyd MR, Yi L, Yang GG, Vyas GN.

Dev Biol (Basel). 2000;102:141-8. Review.

PMID:
10794101
17.

Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41.

O'Keefe BR, Shenoy SR, Xie D, Zhang W, Muschik JM, Currens MJ, Chaiken I, Boyd MR.

Mol Pharmacol. 2000 Nov;58(5):982-92.

19.

Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells.

Mori T, Shoemaker RH, McMahon JB, Gulakowski RJ, Gustafson KR, Boyd MR.

Biochem Biophys Res Commun. 1997 Oct 29;239(3):884-8.

PMID:
9367864
20.

Optimization of scFv antibody production in transgenic plants.

Fiedler U, Phillips J, Artsaenko O, Conrad U.

Immunotechnology. 1997 Oct;3(3):205-16.

PMID:
9358273
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk